Sandy Srinivas

基本信息

Career Trajectory

Bio

Sandy Srinivas specializes in urologic oncology and takes care of patients with prostate, bladder, kidney, testes, penile and adrenal cancers. She has practiced in this field now for more than 20 years . She is the clinical research group leader for Urologic Program at Stanford and is a principal investigator on numerous trials in urologic Oncology and is the medical director for the in-patient hematology Oncology unit . She serves as the Vice chair on the National Comphrehensive Cancer Center (NCCN) panel for prostate cancer and has coauthored numerous publications and book chapters. She has received numerous teaching awards and is a nationally recognized expert in the field of Urologic Oncology.

Research Interests

Papers共 330 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen,Fabio Turco,Ian D. Davis,Jason A. Efstathiou,Karim Fizazi,Nicholas D. James,Neal Shore,Eric Small,Matthew Smith,Christopher J. Sweeney,Bertrand Tombal,Thomas Zilli,Neeraj Agarwal,Emmanuel S. Antonarakis,Ana Aparicio,Andrew J. Armstrong,Diogo Assed Bastos,Gerhardt Attard,Karol Axcrona,Mouna Ayadi,Himisha Beltran,Anders Bjartell,Pierre Blanchard,Maria T. Bourlon,Alberto Briganti,Muhammad Bulbul,Consuelo Buttigliero,Orazio Caffo,Daniel Castellano,Elena Castro,Heather H. Cheng,Kim N. Chi,Caroline S. Clarke,Noel Clarke,Johann S. De Bono,Maria De Santis,Ignacio Duran,Eleni Efstathiou,Onyeanunam N. Ekeke, Tamer I. H. El Nahas,Louise Emmett,Stefano Fanti,Omolara A. Fatiregun,Felix Y. Feng,Peter C. C. Fong,Valerie Fonteyne,Nicola Fossati,Daniel J. George,Martin E. Gleave,Gwenaelle Gravis,Susan Halabi,Daniel Heinrich,Ken Herrmann,Michael S. Hofman,Thomas A. Hope,Lisa G. Horvath,Maha H. A. Hussain,Barbara Alicja Jereczek-Fossa,Robert J. Jones,Anthony M. Joshua, Ravindren Kanesvaran,Daniel Keizman,Raja B. Khauli,Gero Kramer,Stacy Loeb,Brandon A. Mahal,Fernando C. Maluf,Joaquin Mateo,David Matheson, Mika P. Matikainen,Ray McDermott,Rana R. McKay,Niven Mehra,Axel S. Merseburger,Alicia K. Morgans,Michael J. Morris,Hind Mrabti,Deborah Mukherji,Declan G. Murphy,Vedang Murthy,Shingai B. A. Mutambirwa,Paul L. Nguyen,William K. Oh,Piet Ost,Joe M. O'Sullivan,Anwar R. Padhani,Chris Parker,Darren M. C. Poon,Colin C. Pritchard,Danny M. Rabah,Dana Rathkopf,Robert E. Reiter,Raphaele Renard-Penna,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Shahneen Sandhu,Oliver A. Sartor,Edward Schaeffer,Howard I. Scher,Nima Sharifi,Iwona A. Skoneczna,Howard R. Soule,Daniel E. Spratt,Sandy Srinivas,Cora N. Sternberg,Hiroyoshi Suzuki,Mary-Ellen Taplin,Camilla Thellenberg-Karlsson,Derya Tilki,Levent N. Turkeri,Hiroji Uemura,Yuksel Urun,Claire L. Vale,Neha Vapiwala,Jochen Walz,Kosj Yamoah,Dingwei Ye,Evan Y. Yu,Almudena Zapatero,Aurelius Omlin

EUROPEAN UROLOGYno. 2 (2025): 157-216

Cited1Views0WOSBibtex

An Ultrasensitive Method for Detection of Cell-Free RNA

Monica C Nesselbush, Bogdan A Luca,Young-Jun Jeon, Isabel Jabara, Catherine B Meador,Andrea Garofalo,Michael S Binkley,Angela B Hui, Iris van 't Erve, Nova Xu, William Y Shi,Kevin J Liu, Takeshi Sugio,Noah Kastelowitz,Emily G Hamilton,Chih Long Liu,Mari Olsen,Rene F Bonilla, Yi Peng Wang,Alice Jiang,Brianna Lau, Jordan Eichholz, Mandeep Banwait,Joseph Schroers-Martin, Jan Boegeholz, Daniel A King,Helen Luikart,Mohammad S Esfahani,Mahya Mehrmohamadi,Henning Stehr, Tyler Raclin, Robert Tibshirani, Kiran Khush,Sandy Srinivas, Helena Yu,Angela J Rogers, Viswam S Nair,James M Isbell,Bob T Li,Zofia Piotrowska, Lecia V Sequist,Aaron N Hata, Joel W Neal, Heather A Wakelee, Andrew J Gentles,Ash A Alizadeh,Maximilian Diehn

Natureno. 8063 (2025): 759-768

Cited0Views0WOSNATUREBibtex

Safety and Clinical Activity of BMS-986365 (CC-94676), a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer

D. E. Rathkopf,M. R. Patel,A. D. Choudhury,D. Rasco,N. Lakhani,J. E. Hawley,S. Srinivas, A. Aparicio, V. Narayan, K. D. Runcie,H. Emamekhoo,Z. R. Reichert, M. H. Nguyen, A. L. Wells, R. Kandimalla, C. Liu,S. Suryawanshi, J. Han, J. Wu, V. K. Arora,M. Pourdehnad,A. J. Armstrong

ANNALS OF ONCOLOGY（2025）

Cited0Views0WOSBibtex

Lay Healthcare Worker Financial Toxicity Intervention: A Pilot Financial Toxicity Screening and Referral Program

Divya A Parikh,Gladys M. Rodriguez,Meera Ragavan,Elizabeth Kerr,Mary Khay Asuncion,Jennifer Hansen,Sandy Srinivas,Alice C. Fan,Sumit Shah,Manali I. Patel

Supportive Care in Cancer（2024）

Cited0Views0WOSBibtex

A review of mitotane in the management of adrenocortical cancer

Jaydira Del Rivero,Tobias Else,Julie Hallanger-Johnson,Katja Kiseljak-Vassiliades,Nitya Raj,Diane Reidy-Lagunes,Sandy Srinivas,Jill Gilbert,Anand Vaidya, Emily Aboujaoude,Irina Bancos,Antonio Tito Fojo

The oncologistno. 9 (2024): 747-760

Cited0Views0WOSBibtex

First-in-human Phase 1 Study of CC-94676, a First-in-class Androgen Receptor (AR) Ligand-Directed Degrader (LDD), in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Dana E. Rathkopf,Manish R. Patel,Atish Dipankar Choudhury,Drew W. Rasco,Nehal J. Lakhani,Jessica E. Hawley,Ana Aparicio,Vivek Narayan,Sandy Srinivas,Karie Runcie,Hamid Emamekhoo,Zachery R. Reichert,Michael Anthony Carducci, Amber L. Wells, Can Liu,Raju Kandimalla, Jiaju Wu, Marie Huong Nguyen,Michael Pourdehnad,Andrew J. Armstrong

Journal of Clinical Oncologyno. 4_suppl (2024): 134-134

Cited0Views0Bibtex

1597MO Clinical Activity of BMS-986365 (CC-94676), a Dual Androgen Receptor (AR) Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

D. Rathkopf,M.R. Patel,A.D. Choudhury,D. Rasco,N.J. Lakhani, J. Hawley,S. Srinivas, A. Aparicio, V. Narayan, K. Runcie,H. Emamekhoo,Z. Reichert, H. Nguyen, A. Wells, R. Kandimalla, S. Suryawanshi, J. Wu, V. Arora,M. Pourdehnad,A.J. Armstrong

Annals of Oncology (2024): S962-S963

Cited0Views0Bibtex

1968P Study EV-103 Dose Escalation/cohort A (DE/A): 5y Follow-Up of First-Line (1L) Enfortumab Vedotin (EV) + Pembrolizumab (P) in Cisplatin (Cis)-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma (La/muc)

J.E. Rosenberg,D.P. Petrylak,T. Flaig,C.J. Hoimes, S. Gupta,P.H. O'Donnell,N. Mar,T. Friedlander,S.T. Tagawa,M.A. Bilen, J.R. Brown,R.R. McKay,J.R. Merchan,S. Srinivas, A. Shetty,B. Homet Moreno, G. Davis, H. Wirtz, Y. Zhu,M.I. Milowsky

Annals of Oncology (2024): S1139-S1140

Cited0Views0Bibtex

Adjuvant Pembrolizumab Versus Observation in Muscle-Invasive Urothelial Carcinoma

The New England journal of medicineno. 1 (2024): 45-55

Cited2Views0WOSBibtex

1964MO Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab (pembro) in Muscle-Invasive Urothelial Carcinoma (MIUC) Vs Observation (obs): Extended Follow-Up Disease-Free Survival (DFS) Results and Metastatic (met) Disease Recurrence Distribution

A.B. Apolo, K. Ballman,G.P. Sonpavde,S. Berg, W. Kim, R. Parikh,M.Y. Teo,R.F. Sweis,D. Geynisman,P. Grivas,G. Chatta,Z. Reichert, J.W. Kim,M.A. Bilen,B.A. McGregor,S. Srinivas,S. Halabi, G. Perez Burbano,M.J. Morris,J.E. Rosenberg

Annals of Oncology (2024): S1135-S1136

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 330 篇Author StatisticsCo-AuthorSimilar Experts